Heart (British Cardiac Society), 2009-01, Vol.95 (1), p.1-3
2009
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
- Ist Teil von
- Heart (British Cardiac Society), 2009-01, Vol.95 (1), p.1-3
- Ort / Verlag
- England: BMJ Publishing Group Ltd and British Cardiovascular Society
- Erscheinungsjahr
- 2009
- Quelle
- BMJ Journals Archiv - DFG Nationallizenzen
- Beschreibungen/Notizen
- [...]none has been granted regulatory approval for this indication. Pioglitazone lowers triglycerides and raises high-density lipoprotein cholesterol, in contrast to rosiglitazone. 29 30 A recent study showed that pioglitazone regulates inflammatory target genes (soluble vascular cell adhesion molecules-1 (sVCAM-1)) in endothelial settings in a PPAR α-dependent manner, whereas rosiglitazone has no such effect. 31 It is unclear if differential effects on gene regulation may mediate the differences between rosiglitazone and pioglitazone.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1355-6037eISSN: 1468-201XDOI: 10.1136/hrt.2008.155507Titel-ID: cdi_proquest_journals_1780694737
- Format
- –
- Schlagworte
- Cardiovascular disease, Cell adhesion & migration, Clinical trials, Diabetes, Diabetes Mellitus, Type 2 - drug therapy, Diabetic Angiopathies - drug therapy, Disease prevention, Health risk assessment, Heart attacks, Heart failure, Heart Failure - drug therapy, Humans, Hypertension, Mortality, Myocardial Ischemia - drug therapy, Regulatory approval, Retention, Studies, Thiazolidinediones - adverse effects, Thiazolidinediones - therapeutic use, Treatment Outcome